Thalidomide

Catalog No.S1193

Thalidomide was introduced as a sedative drug, immunomodulatory agent and also is investigated for treating symptoms of many cancers. Thalidomide inhibits an E3 ubiquitin ligase, which is a CRBN-DDB1-Cul4A complex.

Price Stock Quantity  
In DMSO USD 190 In stock
USD 147 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Thalidomide Chemical Structure

Thalidomide Chemical Structure
Molecular Weight: 258.23

Validation & Quality Control

Quality Control & MSDS

Related Compound Libraries

Thalidomide is available in the following compound libraries:

Product Information

  • Compare TNF-alpha Inhibitors
    Compare TNF-alpha Products
  • Research Area

Product Description

Biological Activity

Thalidomide was introduced as a sedative drug in the late 1950s. However, it was withdrawn due to a teratogenic effect on fetal development. Thalidomide binds to inactivate the protein cereblon, which is important to limb formation. [1]
There is now a growing clinical interest in thalidomide since it is introduced as an immunomodulatory agent used primarily, combined with dexamethasone, to treat multiple myeloma. The combination of thalidomide and dexamethasone, often in combination with melphalan, is now one of the most common regimens for patients with newly diagnosed multiple myeloma, with an improved response rate of up to 60-70%. [1]

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesBaboonDogMonkeyRabbitGuinea pigRatHamsterMouse
Weight (kg)121031.80.40.150.080.02
Body Surface Area (m2)0.60.50.240.150.050.0250.020.007
Km factor202012128653
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2014-09-01)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02203253 Recruiting Neoplasms China Medical University, China|The First Hospital of Liaoning Medical University|The First Affiliated Hospital of Dalian Medical University|Second Affiliated Hospital of Dalian Medical University|Liaoning Tumor Hospital & Institute|Shengjing Hospital|General Hospital of Shenyang Military Region|Liaoyang Central Hospital|Third Peoples hospital Liaoyang|Petrochemical General Hospital of Liaoyang city|Anshan Tumor Hospital July 2014 Phase 3
NCT01356290 Recruiting Medulloblastoma Medical University of Vienna|Medical University of Graz|Medical University Innsbruck|General Hospital Linz|Salzburger Landeskliniken April 2014 Phase 2
NCT01998971 Recruiting Multiple Myeloma Janssen Research & Development, LLC February 2014 Phase 1
NCT01927718 Recruiting Myeloma M.D. Anderson Cancer Center|Celgene Corporation January 2014 --
NCT01638078 Not yet recruiting Coronary Artery Disease University of Roma La Sapienza January 2014 Phase 4

view more

Chemical Information

Download Thalidomide SDF
Molecular Weight (MW) 258.23
Formula

C13H10N2O4

CAS No. 50-35-1
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Synonyms
Solubility (25°C) * In vitro DMSO 52 mg/mL (201 mM)
Water <1 mg/mL (<1 mM)
Ethanol 2 mg/mL (7 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol, 5 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Research Area

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related TNF-alpha Products

  • Nutlin-3a

    Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM.

    Features:Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.

  • GSK2606414

    GSK2606414 is an orally available, potent, and selective PERK inhibitor with IC50 of 0.4 nM, displaying at least 100-fold selectivity over the other EIF2AKs assayed.

  • GSK2656157

    GSK2656157 is an ATP-competitive and highly selective inhibitor of PERK with IC50 of 0.9 nM, 500-fold greater against a panel of 300 kinases.

  • Lenalidomide (CC-5013)

    Lenalidomide (CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM.

  • Pomalidomide

    Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM.

    Features:A derivative of thalidomide and up to 10,000 times more potent than thalidomide.

  • Necrostatin-1

    Necrostatin-1 is a specific RIP1 inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM.

    Features:A powerful tool for characterizing the role of necroptosis with characterized primary target.

  • ABT-737

    ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

  • ABT-263 (Navitoclax)

    ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM, but binds more weakly to Mcl-1 and A1. Phase 2.

  • ABT-199 (GDC-0199)

    ABT-199 (GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

    Features:Re-engineered version of ABT-263 (Navitoclax).

  • YM155 (Sepantronium Bromide)

    YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. Phase 2.

Recently Viewed Items

Tags: buy Thalidomide | Thalidomide ic50 | Thalidomide price | Thalidomide cost | Thalidomide solubility dmso | Thalidomide purchase | Thalidomide manufacturer | Thalidomide research buy | Thalidomide order | Thalidomide mouse | Thalidomide chemical structure | Thalidomide mw | Thalidomide molecular weight | Thalidomide datasheet | Thalidomide supplier | Thalidomide in vitro | Thalidomide cell line | Thalidomide concentration | Thalidomide nmr
Contact Us